NCT03888053View on ClinicalTrials.gov

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

December 1, 2021

Study Completion Date

December 31, 2023

Conditions
Diabetic Foot Ulcer
Interventions
BIOLOGICAL

BB-101

Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.

Trial Locations (1)

Unknown

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

Blue Blood Biotech Corp.

INDUSTRY

NCT03888053 - BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers | Biotech Hunter | Biotech Hunter